# Antiviral Agents Against COVID-19 Infection

> **NCT04468087** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hospital do Coracao** · enrollment: 256 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Daclatasvir 60 mg
- **DRUG:** Sofusbuvir + Daclastavir 60 mg
- **DRUG:** Placebo Atazanavir
- **DRUG:** Placebo Daclatasvir 60 mg
- **DRUG:** Placebo Sofusbuvir + Daclatasvir 60 mg

## Key facts

- **NCT ID:** NCT04468087
- **Lead sponsor:** Hospital do Coracao
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2021-08-04
- **Final completion:** 2021-08-04
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04468087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04468087, "Antiviral Agents Against COVID-19 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04468087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*